Literature DB >> 19570538

Metabolism and atherogenic disease association of lysophosphatidylcholine.

Gerd Schmitz1, Katharina Ruebsaamen.   

Abstract

Lysophosphatidylcholine (LPC) is a major plasma lipid that has been recognized as an important cell signalling molecule produced under physiological conditions by the action of phospholipase A(2) on phosphatidylcholine. LPC transports glycerophospholipid components such as fatty acids, phosphatidylglycerol and choline between tissues. LPC is a ligand for specific G protein-coupled signalling receptors and activates several second messengers. LPC is also a major phospholipid component of oxidized low-density lipoproteins (Ox-LDL) and is implicated as a critical factor in the atherogenic activity of Ox-LDL. Hence, LPC plays an important role in atherosclerosis and acute and chronic inflammation. In this review we focus in some detail on LPC function, biochemical pathways, sources and signal-transduction system. Moreover, we outline the detection of LPC by mass spectrometry which is currently the best method for accurate and simultaneous analysis of each individual LPC species and reveal the pathophysiological implication of LPC which makes it an interesting target for biomarker and drug development regarding atherosclerosis and cardiovascular disorders. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570538     DOI: 10.1016/j.atherosclerosis.2009.05.029

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  107 in total

1.  Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells.

Authors:  Kasey C Vickers; Fernando Castro-Chavez; Joel D Morrisett
Journal:  Atherosclerosis       Date:  2010-04-14       Impact factor: 5.162

2.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

3.  Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging.

Authors:  Marta Gonzalez-Freire; Ruin Moaddel; Kai Sun; Elisa Fabbri; Pingbo Zhang; Mohammed Khadeer; Norman Salem; Luigi Ferrucci; Richard D Semba
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2019-01-01       Impact factor: 6.053

4.  Inhibition of Caspase-1 Activation in Endothelial Cells Improves Angiogenesis: A NOVEL THERAPEUTIC POTENTIAL FOR ISCHEMIA.

Authors:  Jahaira Lopez-Pastrana; Lucas M Ferrer; Ya-Feng Li; Xinyu Xiong; Hang Xi; Ramon Cueto; Jun Nelson; Xiaojin Sha; Xinyuan Li; Ann L Cannella; Princess I Imoukhuede; Xuebin Qin; Eric T Choi; Hong Wang; Xiao-Feng Yang
Journal:  J Biol Chem       Date:  2015-06-02       Impact factor: 5.157

5.  Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis.

Authors:  Zohara Sternberg; Alison Drake; Daniel S Sternberg; Ralph H B Benedict; Fan Li; David Hojnacki; Bianca Weinstock-Guttmann; Frederick E Munschauer
Journal:  J Clin Immunol       Date:  2012-01-13       Impact factor: 8.317

6.  The Lysophosphatidylcholine Transporter MFSD2A Is Essential for CD8+ Memory T Cell Maintenance and Secondary Response to Infection.

Authors:  Ann R Piccirillo; Eric J Hyzny; Lisa Y Beppu; Ashley V Menk; Callen T Wallace; William F Hawse; Heather M Buechel; Bernice H Wong; Juat Chin Foo; Amaury Cazenave-Gassiot; Markus R Wenk; Greg M Delgoffe; Simon C Watkins; David L Silver; Louise M D'Cruz
Journal:  J Immunol       Date:  2019-05-24       Impact factor: 5.422

7.  Lysophospholipid presentation by CD1d and recognition by a human Natural Killer T-cell receptor.

Authors:  Jacinto López-Sagaseta; Leah V Sibener; Jennifer E Kung; Jenny Gumperz; Erin J Adams
Journal:  EMBO J       Date:  2012-03-06       Impact factor: 11.598

8.  Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement.

Authors:  Dorothea Lesche; Vilborg Sigurdardottir; Alexander B Leichtle; Christos T Nakas; Uwe Christians; Lars Englberger; Martin Fiedler; Carlo R Largiadèr; Paul Mohacsi; Johanna Sistonen
Journal:  Metabolomics       Date:  2017-11-25       Impact factor: 4.290

9.  Lysophospholipids and their G protein-coupled receptors in atherosclerosis.

Authors:  Ya-Feng Li; Rong-Shan Li; Sonia B Samuel; Ramon Cueto; Xin-Yuan Li; Hong Wang; Xiao-Feng Yang
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01-01

Review 10.  In vivo metabolite profiling as a means to identify uncharacterized lipase function: recent success stories within the alpha beta hydrolase domain (ABHD) enzyme family.

Authors:  Gwynneth Thomas; Amanda L Brown; J Mark Brown
Journal:  Biochim Biophys Acta       Date:  2014-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.